濮阳东方男科很好(濮阳东方医院男科看早泄价格收费透明) (今日更新中)

When Allison Weiss Brady and Michael Ladin emerged from weeks of locking down during the pandemic, they needed new clothes in new sizes — for different reasons.Brady, 49, a charity fundraiser from a Philadelphia suburb, had been pulling back on her candy buying sprees during the lockdown and stepped up the cardio workouts at her home gym out of boredom. She lost 20 pounds and went down two sizes. In contrast, Ladin, 58, of Oak Park, Illinois, gained 10 pounds this past spring after sitting around eating chips and dip.“I’m not surprised. If I don’t work out consistently, I gain weight,” said Ladin, who works in marketing.Many Americans like Ladin and Brady are changing clothing sizes depending on how they spent their time sheltering at home. And brands from Levi Strauss & Co. to lingerie label Cosabella are taking note. So are body measuring technology companies, which report that shoppers are changing their measurements on their online profiles.The trend could be good for clothing companies — new sizes likely mean that customers’ wardrobes need to be updated. But retailers, already feeling the pain of decreased spending during uncertain economic times, are also facing an increase in costly returns as shoppers try to figure out their new sizes.“Anecdotally, we’re seeing shoppers come back into stores unsure of their size,” said Marc Rosen, executive vice president and president of Levi Strauss Americas, in a statement to The Associated Press. “For most, it’s been a long time since they’ve tried on a pair of jeans, and they may be up or down a size.”Some companies are even adding larger sizes in response to shoppers’ gaining weight, or what has been dubbed COVID-15.Guido Campello, co-CEO of luxury lingerie brands Cosabella and Journelle, said that his two brands have been adding more generous cuts of some of its most popular styles in bras and sleepwear in recent weeks because of interest from its 2,100 store accounts. Loyal customers at its store locations are also requesting new sizes while making more exchanges.Size fluctuations are bearing out in data from body measuring app Perfitly LLC. It cites a 20% increase in users redoing their avatars in April and May, compared with the same period a year ago, according to the company’s co-founder and CEO Dave Sharma. That spike is similar to what it sees in January after the winter holidays, he says.“Because it is a huge spike, we think it is because of the weight gain,” said Sharma, whose app has about 50,000 users nationwide. “They are sitting around, they don’t go to the gym, and they don’t go for jogs.”Fit Match, a startup firm that’s rolling out 3D technology to scan customers bodies at malls, found only one-third of the hundred women it surveyed in Texas where it piloted its first program had no weight change during the lockdown, says founder and CEO Haniff Brown. Of the remainder, 15% gained more than 5 pounds, while 20% lost more than five pounds. Brown called this change “pronounced,” noting two-thirds of customers typically don’t have any weight change during such a short time period.Narvar Inc., a software company that powers returns for more than 200 brands, says online returns have doubled from mid-March to early June, according to founder and CEO Amit Sharma. Retailers face more than 0 million in expenses from the additional returns in the second quarter, in part because of sizing issues but also because of buyers’ remorse and shipping delays.Brady took advantage of sales and spent several thousands of dollars in recent weeks on a new wardrobe that included, T-shirts, inexpensive summer dresses, and designer sweatshirts. She also sent her new measurements to her personal shoppers at Neiman Marcus and Saks.“I feel great. My (old) clothes are huge,” said Brady, who hadn’t modeled in years but was recently hired on by a local agency.Still, weight fluctuations may be here to stay as surges in new cases around the country force states like California to re-close businesses like gyms and encourage shoppers to shelter at home again.Lauren Wire a 32-year-old publicist who lives in Manhattan, says she worries that another lock down could keep her gym closed during the winter months.She gained back 12 of the 50 pounds she lost leading up to the pandemic because she was ordering in a lot from restaurants and partaking in social distance cocktails with friends. She says she bought new shorts and swimwear when she gained the weight but now she’s starting to shed pounds again by biking outside.Ladin went to a local Kohl’s to buy several pairs of shorts.“This will be enough to get me through the summer,” he said, trying on his new clothes in the Kohl’s parking lot because the store’s fitting room was temporarily closed out of safety concerns. “I am not buying any more clothes until I lose weight.”__________Follow Anne D’Innocenzio: http://twitter.com/ADInnocenzio 4912

When it comes to scaring us, Hollywood sure likes to have fun with spiders. But it's no fun when you have a real fear of them. So it's no surprise when it came time to see one in person, Cassandra Kidd was a bit nervous.  "Oh God I'm scared!" Kidd exclaimed.   She mustered up her strength to hold Rosie the tarantula. And after just a few seconds the fear was gone.  "It felt kind of like a ladybug but more gentle," Kidd says.    Kathleen Lewis peered over the wall as her grandson held Rosie.  "No I'm not as brave as my four-year-old grandson," Lewis says.  Fear kept her from holding the spider herself.  "Too many legs moving," Lewis says.When it comes to overcoming fears like Arachnophobia experts say educating yourself in an environment where you feel safe can make all the difference. The Spider Pavilion at Butterfly Pavilion is an example. Arachnids of all sizes hang out above.  A belief that spiders want to jump down on you is one of many misconceptions Mary Ann Colley, Vice President of Science and Conservation at Butterfly Pavilion, has heard about spiders.  "People are always saying, 'Oh, I am going to eat spiders in my sleep,'" Colley says. "That's not true."Another? The idea they want to bite you."Spiders really don't want to have anything to do with us," Colley says. "They want to do their own thing, they want to hunt for their food, create their webs."  Colley says only a small amount of spiders have a level of toxicity to actually hurt us. Butterfly Pavilion hopes sharing facts can help overcome fear."We want to be respectful of nature around us," Colley says. "So we always suggest to observe so just to take a look you can get close but you don't have to touch."  Seeing spiders in a new light. And facing your fear head on. 1850

What’s sweeter than saying “bye” to the worst year ever? Pepsi “Cocoa” Cola - the latest concept from the Pepsi Test Kitchen. Want to try and get your hands on it? 2,021 RTs and we’ll make a batch.#PepsiCocoaCola pic.twitter.com/WbZeGDGxVM— Pepsi (@pepsi) December 17, 2020 287

With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies to fight the virus right away, without having to train the immune system to make them.Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines work by tricking the body into thinking there’s an infection so it makes antibodies and remembers how to do that if the real bug turns up.But it can take a month or two after vaccination or infection for the most effective antibodies to form. The experimental drugs shortcut that process by giving concentrated versions of specific ones that worked best against the coronavirus in lab and animal tests.“A vaccine takes time to work, to force the development of antibodies. But when you give an antibody, you get immediate protection,” said University of North Carolina virologist Dr. Myron Cohen. “If we can generate them in large concentrations, in big vats in an antibody factory ... we can kind of bypass the immune system.”These drugs are believed to last for a month or more and could give quick, temporary immunity to people at high risk of infection, such as health workers and housemates of someone with COVID-19. If they proved effective and if a vaccine doesn’t materialize or protect as hoped, the drugs might eventually be considered for wider use, perhaps for teachers or other groups.They’re also being tested as treatments, to help the immune system and prevent severe symptoms or death.“The hope there is to target people who are in the first week of their illness and that we can treat them with the antibody and prevent them from getting sick,” said Dr. Marshall Lyon, an infectious disease specialist helping to test one such drug at Emory University in Atlanta.Having such a tool “would be a really momentous thing in our fight against COVID,” Cohen said.Vaccines are seen as a key to controlling the virus, which has been confirmed to have infected more than 20 million people worldwide and killed more than 738,000. Several companies are racing to develop vaccines, but the results of the large final tests needed to evaluate them are months away.The antibody drugs are “very promising” and, in contrast, could be available “fairly soon,” said Dr. Janet Woodcock, a U.S. Food and Drug Administration official who is leading government efforts to speed COVID-19 therapies. Key studies are underway and some answers should come by early fall.One company, Eli Lilly, has already started manufacturing its antibody drug, betting that studies now underway will give positive results.“Our goal is to get something out as soon as possible” and to have hundreds of thousands of doses ready by fall, said Lilly’s chief scientific officer, Dr. Daniel Skovronsky.Another company that developed an antibody drug cocktail against Ebola — Regeneron Pharmaceuticals Inc. — now is testing one for coronavirus.“The success with our Ebola program gives us some confidence that we can potentially do this again,” said Christos Kyratsous, a Regeneron microbiologist who helped lead that work.Regeneron’s drug uses two antibodies to enhance chances the drug will work even if the virus evolves to evade action by one.Lilly is testing two different, single-antibody drugs — one with the Canadian company AbCellera and another with a Chinese company, Junshi Biosciences. In July, Junshi said no safety concerns emerged in 40 healthy people who tried it and that larger studies were getting underway.Others working on antibody drugs include Amgen and Adaptive Biotechnologies. The Singapore biotech company Tychan Pte Ltd. also is testing an antibody drug and has similar products in development for Zika virus and yellow fever.“I’m cautiously optimistic” about the drugs, said the nation’s top infectious diseases expert, Dr. Anthony Fauci. “I’m heartened by the experience that we had with Ebola,” where the drugs proved effective.What could go wrong?— The antibodies may not reach all of the places in the body where they need to act, such as deep in the lungs. All the antibody drugs are given through an IV and must make their way through the bloodstream to wherever they’re needed.— The virus might mutate to avoid the antibody — the reason Regeneron is testing a two-antibody combo that binds to the virus in different places to help prevent its escape.Skovronsky said Lilly stuck with one antibody because manufacturing capacity would essentially be cut in half to make two, and “you will have less doses available.” If a single antibody works, “we can treat twice as many people,” he said.— The antibodies might not last long enough. If they fade within a month, it’s still OK for treatment since COVID-19 illness usually resolves in that time. But for prevention, it may not be practical to give infusions more often than every month or two.A San Francisco company, Vir Biotechnology Inc., says it has engineered antibodies to last longer than they usually do to avoid this problem. GlaxoSmithKline has invested 0 million in Vir to test them.Giving a higher dose also may help. If half of antibodies disappear after a month, “if you give twice as much, you will have two months’ protection,” Lilly’s Skovronsky said.— The big fear: Antibodies may do the opposite of what’s hoped and actually enhance the virus’s ability to get into cells or stimulate the immune system in a way that makes people sicker. It’s a theoretical concern that hasn’t been seen in testing so far, but large, definitive experiments are needed to prove safety.“As best as we can tell, the antibodies are helpful,” Lyon said.___Marilynn Marchione can be followed on Twitter: @MMarchioneAP___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5919

While most Republicans have remained silent on Saturday after Joe Biden being was projected to win this week's presidential election, a handful of Republican office holders offered congratulations for Biden. Most notably, Mitt Romney, who voted to impeach Donald Trump, was among the first Republicans to issue a statement. 332

来源：资阳报